Indivior Rated Overweight with 113% EPS Growth and 76% Market Share
INDV•Barclays initiated an Overweight rating on Indivior PLC, citing Sublocade’s 76% market share, 88% payer coverage and a low 9% adoption rate in the opioid treatment segment. Indivior’s Q1 adjusted EPS rose 113.3% to $0.96, driving management to increase 2026 revenue and EBITDA guidance.
1. Overweight Rating by Barclays
Barclays initiated coverage on Indivior PLC with an Overweight rating, projecting superior sector performance based on addiction treatment market expansion and Indivior’s leadership in long-acting injectable therapies.
2. Sublocade Market Leadership
Sublocade holds a 76% share of the long-acting opioid use disorder segment and secures 88% payer coverage, yet current market adoption is only 9%, pointing to significant growth potential as healthcare providers favor monthly treatments over daily dosing.
3. Q1 Results and Guidance Raise
Indivior reported a 113.3% increase in adjusted EPS to $0.96 in Q1, driven by a 32% rise in Sublocade revenue from higher volumes and pricing; this performance led management to raise full-year revenue and EBITDA targets for 2026.
4. Financial Strength Measures
The company repurchased shares and refinanced debt to reduce interest costs, reinforcing its balance sheet and underpinning capacity for continued investment in market expansion and R&D.
